Integral Derivatives’s CorMedix CRMD Stock Holding History

Integral Derivatives’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,740	Closed	-$21K	–	1192
2016 Q4	$21K	Buy	+2,740	New	+$27.7K	﹤0.01%	1104

Other funds holding CRMD

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GLRA

Gerald L. Ray & Associates Dallas, Texas $802M AUM 21.01% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Integral Derivatives's CRMD Position: Q1 2017 in Review

Integral Derivatives sold out of CorMedix (CRMD) in Q1 2017, closing a stake of 2,280 shares — an estimated $17K sold.

Integral Derivatives first reported a position in CRMD in Q4 2016 and held it in 1 quarter. The position peaked at $17K in Q4 2016. 30 funds tracked by Wall St. Rank hold CRMD as of Q1 2017.

Integral Derivatives reported no remaining CorMedix position as of Q1 2017 after selling out during the quarter.
Integral Derivatives sold 2,280 CorMedix shares in Q1 2017, an estimated $17K.
Integral Derivatives first reported a position in CorMedix in Q4 2016 and held it in 1 quarter.
Integral Derivatives's CorMedix position peaked at $17K in Q4 2016.
30 funds tracked by Wall St. Rank held CorMedix as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.